Pulmonary Fibrosis News and Research

RSS

Celgene second-quarter non-GAAP total revenue increases 36% to $850 million

Celgene Corporation announced non-GAAP net income of $323.3 million, or non-GAAP diluted earnings per share of $0.69 for the quarter ended June 30, 2010. Non-GAAP net income for the second quarter of 2009 was $216.0 million or non-GAAP diluted earnings per share of $0.46.

29 Jul 2010

InterMune second-quarter total revenue decreases to $5.9 million

InterMune, Inc. today announced results from operations for the second quarter and six months ended June 30, 2010. InterMune also highlighted its recent clinical development and business activities, and provided forward-looking financial guidance for 2010.

28 Jul 2010

Activities of TAT fully consolidated into Geron

Geron Corporation today announced that the activities of TA Therapeutics, its joint venture with Hong Kong University of Science and Technology, are being fully consolidated into Geron.

15 Jul 2010

FDA grants Angion Biomedica's BB3 therapeutic Fast Track and Orphan Drug product designations

Angion Biomedica Corp., a biopharmaceutical company dedicated to the discovery and development of novel therapeutics that enhance quality of life, eradicate disease and save lives by modulating the body's protective, reparative and regenerative systems, announced today that its lead therapeutic BB3 was accepted into the Fast Track program of the U.S. Food and Drug Administration (FDA) and has also been designated an Orphan Drug product by FDA.

7 Jul 2010

NBC's TODAY Show to focus on PF in an interview with a patient from California

The Coalition for Pulmonary Fibrosis announced today one of the first major national media coverage opportunities for the CPF and Pulmonary Fibrosis. NBC's TODAY Show will focus on the disease in an interview with California patient Bob O'Rourke, who suffers from the disease and will die from it unless he receives a lung transplant in time.

15 Jun 2010

NeoPharm first-quarter net loss decreases to $1.4 million

NeoPharm, Inc., a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced its first quarter 2010 financial results.

11 Jun 2010

Zargis Medical signs exclusive license agreement with Boston-based Stethographics

Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it has entered into an agreement with Boston-based Stethographics, Inc. providing an exclusive license to patented, FDA-cleared Stethographics lung sounds analysis technology that automatically identifies clinically significant respiratory sounds.

11 Jun 2010

Highlights from June 2010 issue of American Journal of Pathology

Dr. Kanneboyina Nagaraju and colleagues at the Children's National Medical Center, Washington, DC demonstrate that affected muscle may directly contribute to inflammation in muscular dystrophy. Their report can be found in the June 2010 issue of The American Journal of Pathology.

26 May 2010

2010 funding program for Inova Life Sciences - George Mason University research collaboration open

What do you get when you mix a world-class health system with an innovative, entrepreneurial university? A very successful research collaboration.

20 May 2010

Positive data from Geron's TAT153 small molecule telomerase activator in animal model of IPF

Geron Corporation today announced positive data on its orally available small molecule telomerase activator, TAT153, in an animal model of idiopathic pulmonary fibrosis (IPF). The data show that administration of TAT153 increased telomerase activity in the lung tissue, reduced inflammation, preserved functional lung tissue, slowed disease progression and attenuated loss of pulmonary function.

19 May 2010

NAC therapy shows promise for patients with mild IPF

A new therapy shows promise for patients with mild idiopathic pulmonary fibrosis. According to researchers in Japan, inhaled N-acetylcysteine monotherapy preserves more lung function in some idiopathic pulmonary fibrosis patients than no therapy.

19 May 2010

FDA grants NeoPharm's IL13-PE38QQR orphan-drug designation for treatment of IPF

NeoPharm, Inc., announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan-drug designation for IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

17 May 2010

Amira Pharmaceuticals' LPA1 receptor antagonist program data published in British Journal of Pharmacology

Amira Pharmaceuticals, Inc. announced today that preclinical data from its LPA1 receptor antagonist program has been published in the British Journal of Pharmacology.

7 May 2010

FDA's call for further review of pirfenidone disappointing for Pulmonary Fibrosis patients, says CPF

The Coalition for Pulmonary Fibrosis (CPF), representing tens of thousands of patients, is responding to the news that the FDA chose to ask for further study of Pirfenidone, which will delay potential approval of the first drug in the treatment of Pulmonary Fibrosis (PF), a lethal lung disease that is irreversible, progressive and deadly in an average of three years. On March 9, 2010, an FDA Advisory Committee recommended approval of the drug by the FDA.

5 May 2010

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Celgene Corporation announced non-GAAP net income of $294.6 million, or non-GAAP diluted earnings per share of $0.63 for the quarter ended March 31, 2010. Non-GAAP net income for the first quarter of 2009 was $205.1 million or non-GAAP diluted earnings per share of $0.44. Based on U.S. GAAP, Celgene reported net income of $234.4 million, or diluted earnings per share of $0.50 for the quarter ended March 31, 2010. GAAP net income for the first quarter of 2009 was $162.9 million, or diluted earnings per share of $0.35.

29 Apr 2010

Small piece of RNA plays big role in development of IPF: Researchers

A small piece of RNA appears to play a big role in the development of idiopathic pulmonary fibrosis (IPF), according to lung disease researchers at the University of Pittsburgh School of Medicine. Their study, which is the first to examine microRNAs in the disease, is available online in the American Journal of Respiratory and Critical Care Medicine.

29 Apr 2010

Three nonprofit organizations launch campaign to increase national awareness of PF

The Coalition for Pulmonary Fibrosis, The Pulmonary Fibrosis Foundation and the Pulmonary Fibrosis Association of Texas today announced the launch of a special, grassroots campaign to build increased national awareness of Pulmonary Fibrosis.

12 Apr 2010

U-M Medical School researchers earn $366M in NIH research funding in fiscal year 2009

University of Michigan Medical School physicians and scientists earned more than $366 million in National Institutes of Health research funding in federal fiscal year 2009, according to NIH data. In all, the School's faculty brought in more than $435 million in research funding from all sources in U-M fiscal year 2009.

12 Apr 2010

Updated report analyzing approval rates at FDA published

Sagient Research Systems, a leading publisher of independent research for the financial services, institutional investment and corporate intelligence communities, recently published an updated report analyzing approval rates at the U.S Food and Drug Administration. According to its research service, BioMedTracker, the rate of drugs that were approved by the FDA in 2008 and 2009 has remained close to the historical low seen in 2007.

7 Apr 2010

Lung transplant patients may one day benefit from synthetic peptide, researchers report

Lung transplant patients may one day benefit from a synthetic peptide that mimics the body's natural ability to reduce excess fluid accumulation, Medical College of Georgia researchers report.

26 Mar 2010